NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
9.67
+0.86 (9.80%)
At close: Oct 29, 2025, 4:00 PM EDT
9.87
+0.20 (2.04%)
After-hours: Oct 29, 2025, 6:14 PM EDT
NTHI Revenue
NeOnc Technologies Holdings had revenue of $59.99K in the twelve months ending June 30, 2025, down -4.78% year-over-year. In the year 2024, NeOnc Technologies Holdings had annual revenue of $83.00K with 17.79% growth.
Revenue (ttm)
$59.99K
Revenue Growth
-4.78%
P/S Ratio
2,982.93
Revenue / Employee
$7,499
Employees
8
Market Cap
185.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83.00K | 12.54K | 17.79% |
| Dec 31, 2023 | 70.46K | 50.46K | 252.31% |
| Dec 31, 2022 | 20.00K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNTHI News
- 20 days ago - NeOnc Technologies: From Survival Mode To Expansion Mode - Seeking Alpha
- 20 days ago - NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors - GlobeNewsWire
- 4 weeks ago - NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board - GlobeNewsWire
- 7 weeks ago - Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy - GlobeNewsWire
- 7 weeks ago - NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer - GlobeNewsWire
- 2 months ago - NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board - GlobeNewsWire
- 2 months ago - NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation - GlobeNewsWire
- 2 months ago - NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia - GlobeNewsWire